•  
  •  
 

Document Type

Original Article

Abstract

Background: Erectile Dysfunction (ED) is the inability to sustain an erection that is firm enough to engage in satisfactory sexual intercourse. Previous literature reported a link between hyperuricemia and ED, and others found Allopurinol could reduce the risk of ED in patients with hyperuricemia. Aim: We aim in our study to assess the impact of hyperuricemia on ED and the effect of Allopurinol on this population either alone or with Tadalafil. Methods: We recruited a sample of 80 participants. Patients with Vasculogenic ED and hyperuricemia underwent Uric acid (U.A.) measurement before and after receiving Allopurinol for two months then after receiving Allopurinol plus Tadalafil daily dose for another two months. The participants were divided into three groups based on their baseline International Index of Erectile Function questionnaire (IIEF-5): mild to moderate ED, mild ED, and no ED. Results: Baseline U.A. levels and IIEF5 showed significant variation among all groups (p < 0.001). Similarly, IIEF5 scores at two months (p < 0.001) and 2-month U.A. levels (p < 0.001) significantly differed among groups. IIEF5 scores at four months also showed significant differences (p < 0.001), while 4-month U.A. levels did not (p > 0.05). Participants' comparison at the different time points revealed highly significant differences in all the variables being compared (p-values >below 0.001). Conclusion: Substantial differences were observed in U.A. levels and IIEF5 scores at baseline, two months, and four months, indicating the efficacy of Allopurinol alone and Allopurinol plus Tadalafil in decreasing U.A. levels and improvement of ED.

Keywords

Erectile dysfunction; Uric acid; Allopurinol; International Index of Erectile Function questionnaire (IIEF5); Tadalafil

Subject Area

Dermatology

Download

Share

COinS